Prostate-specific antigen: an evolving role in diagnosis, monitoring, and treatment evaluation in prostate cancer (Q37671112)

21 August 2017

1 reference

title

Prostate-specific antigen: an evolving role in diagnosis, monitoring, and treatment evaluation in prostate cancer (English)

1 reference

21 August 2017

0 references

1 reference

Heather Payne

1

1 reference

21 August 2017

Philip Cornford

series ordinal

2

1 reference

21 August 2017

publication date

8 January 2010

1 reference

21 August 2017

1 reference

21 August 2017

volume

29

1 reference

21 August 2017

issue

6

1 reference

21 August 2017

page(s)

593-601

1 reference

Prostate-specific antigen and prostate cancer: prediction, detection and monitoring.

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.11.003

A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.11.003

Critical appraisal of prostate-specific antigen in prostate cancer screening: 20 years later.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.11.003

PSA updated: still relevant in the new millennium?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.11.003

Associations of lifestyle and physiologic factors with prostate-specific antigen concentrations: evidence from the National Health and Nutrition Examination Survey (2001-2004).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.11.003

7 January 2021

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.11.003

Prostate cancer incidence and mortality rates and trends in the United States and Canada

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.11.003

The discovery of prostate specific antigen as a biomarker for the early detection of adenocarcinoma of the prostate.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.11.003

Screening for prostate cancer--the controversy that refuses to die.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.11.003

American Cancer Society guidelines for the early detection of cancer: update of early detection guidelines for prostate, colorectal, and endometrial cancers. Also: update 2001--testing for early lung cancer detection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.11.003

Screening and prostate-cancer mortality in a randomized European study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.11.003

Mortality results from a randomized prostate-cancer screening trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.11.003

Screening for prostate cancer in U.S. men ACPM position statement on preventive practice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.11.003

Tyrol Prostate Cancer Demonstration Project: early detection, treatment, outcome, incidence and mortality

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.11.003

Screening decreases prostate cancer mortality: 11-year follow-up of the 1988 Quebec prospective randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.11.003

Screening, treatment, and prostate cancer mortality in the Seattle area and Connecticut: fifteen-year follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.11.003

Benefits and harms of prostate-specific antigen screening for prostate cancer: an evidence update for the U.S. Preventive Services Task Force

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.11.003

How effective are breast cancer screening programmes by mammography? Review of the current evidence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.11.003

Predicting the risk of a false-positive test for women following a mammography screening programme

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.11.003

Prostate Testing for Cancer and Treatment (ProtecT) feasibility study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.11.003

PSA in the new millennium: a powerful predictor of prostate cancer prognosis and radical prostatectomy outcomes--results from the SEARCH database.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.11.003

Prostate-specific antigen improves the ability of clinical stage and biopsy Gleason sum to predict the pathologic stage at radical prostatectomy in the new millennium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.11.003

Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.11.003

Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.11.003

Biochemical and clinical significance of the posttreatment prostate-specific antigen bounce for prostate cancer patients treated with external beam radiation therapy alone: a multiinstitutional pooled analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.11.003

Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.11.003

Persistent prostate-specific antigen expression after neoadjuvant androgen depletion: An early predictor of relapse or incomplete androgen suppression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.11.003

Androgen-Independent Prostate Cancer Is a Heterogeneous Group of Diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.11.003

Surrogate endpoints in clinical trials: definition and operational criteria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.11.003

Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.11.003

Measuring therapeutic efficacy in the changing paradigm of castrate-resistant prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.11.003

Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.11.003

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.11.003

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.11.003

Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.11.003

Prostate-specific antigen (PSA) as a surrogate end point for survival in prostate cancer clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.11.003

Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.11.003

A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.11.003

Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.11.003

Targeted therapy in prostate cancer--are we our own worst enemy?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.11.003

Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 tria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.11.003

Specific endothelin-A receptor antagonism for the treatment of advanced prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.11.003

Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.11.003

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.11.003

Early prostate-specific antigen changes and the diagnosis and prognosis of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.11.003

Beyond PSA: utility of novel tumor markers in the setting of elevated PSA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.11.003

Biomarkers for prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.11.003

Prognostic significance of circulating tumor cells in patients with hormone refractory prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.11.003

Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.11.003

CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.11.003

Early identification of individuals with prostate cancer in negative biopsies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.11.003

EPCA-2: a highly specific serum marker for prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.11.003

alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.11.003

A novel diagnostic test for prostate cancer emerges from the determination of alpha-methylacyl-coenzyme a racemase in prostatic secretions.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.11.003

A duplex quantitative polymerase chain reaction assay based on quantification of alpha-methylacyl-CoA racemase transcripts and prostate cancer antigen 3 in urine sediments improved diagnostic accuracy for prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.11.003

APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.11.003

The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.11.003

Range of self-tests available to buy in the United Kingdom: an Internet survey.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.11.003

10.1016/J.UROLONC.2009.11.003

7 January 2021

Identifiers

DOI

1 reference

21 August 2017

1 reference